Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Tomich

Dermatology Wilmington, MA Medical Doctor

NPI 1295705994 CMS profile 58213

500 Salem St, Winchester Hiospital Medical Center, Wilmington, MA 01887

Open in the dashboard

General payments

$1,252

66 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Tomich of Wilmington, MA is reported in the CMS Open Payments database as having received $1,252 across 66 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 38th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $44 2
2021 General $29 1
2020 General $202 10
2019 General $977 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Tomich
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to John Tomich were reported at $44. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year John Tomich Dermatology median Middle half National median
2019 $977 $454 $129–$1,240 $163
2020 $202 $235 $81–$756 $114
2021 $29 $377 $108–$1,108 $132
2022 $0 $514 $143–$1,391 $149
2023 $0 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $44 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. LEO Pharma Inc. $193 10 payments
  2. Pfizer Inc. $192 13 payments
  3. AbbVie, Inc. $177 9 payments
  4. Regeneron Healthcare Solutions, Inc. $100 3 payments
  5. Lilly USA, LLC $98 5 payments
  6. Novartis Pharmaceuticals Corporation $96 5 payments
  7. Janssen Biotech, Inc. $80 4 payments
  8. Amgen Inc. $63 4 payments
  9. UCB, Inc. $48 3 payments
  10. Gilead Sciences, Inc. $44 2 payments
  11. Other $159 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,252 66 payments
Products named General payments · program years 2019–2025
  1. ENSTILAR $193 10 payments
  2. EUCRISA $192 13 payments
  3. SKYRIZI $158 7 payments
  4. HUMIRA $113 6 payments
  5. DUPIXENT $100 3 payments
  6. TALTZ $98 5 payments
  7. COSENTYX $80 4 payments
  8. TREMFYA $80 4 payments
  9. Cimzia $48 3 payments
  10. Enbrel $48 3 payments
  11. Other $168 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

546

Median for Dermatology: 534

Drug cost

$325,946

Median for Dermatology: $67,151

Branded share of claims

22.5%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 37 $137,740
Taltz Syringe Ixekizumab Brand 11 $92,783
Taltz Autoinjector Ixekizumab Brand 12 $81,607
Doxycycline Hyclate Generic 83 $3,073
Fluorouracil Generic 61 $3,000
Triamcinolone Acetonide Generic 121 $1,397
Metronidazole Generic 28 $1,248
Cyclosporine Modified Cyclosporine, Modified Brand 12 $1,057
Betamethasone Diprop Augmented Betamethasone/Propylene Glyc Brand 17 $945
Minoxidil Generic 62 $851

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$260,703

Of which drugs: $180

Medicare patients

588

Average age 76

Services billed

3,175

320 women, 268 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 42%
Chronic kidney disease 24%
Ischemic heart disease 23%
Diabetes 19%
Atrial fibrillation 18%
Cancer 17%
Osteoporosis 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 31 245 $180

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

66 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record